High rates of blood transfusion associated with Parkinson's disease.
Blood Transfusion
Gastrointestinal bleeding
Hematology
Parkinson’s disease
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
04
11
2021
accepted:
03
04
2022
pubmed:
3
5
2022
medline:
6
8
2022
entrez:
2
5
2022
Statut:
ppublish
Résumé
As evidence continues to accumulate regarding the multi-organ dysfunction associated with Parkinson's disease (PD), it is still unclear as to whether PD increases the risk of hematological pathology. In this study, the authors investigate the association between PD and hematological pathology risk factors. This retrospective cohort analysis was conducted using 8 years of the National Readmission Database. All individuals diagnosed with PD were queried at the time of primary admission. Readmissions, complications, and risk factors were analyzed at 30-, 90-, 180-, and 300-day intervals. Statistical analysis included multivariate Gaussian-fitted modeling using age, sex, comorbidities, and discharge weights as covariates. Coefficients of model variables were exponentiated and interpreted as odds ratios. The database query yielded 1,765,800 PD patients (mean age: 76.3 ± 10.4; 44.1% female). Rates of percutaneous blood transfusion in readmitted patients at 30, 90, 180, and 300 days were found to be 8.7%, 8.6%, 8.3%, and 8.3% respectively. Those with anti-parkinsonism medication side effects at the primary admission had increased rates of gastrointestinal (GI) hemorrhage (OR: 1.02; 95%CI: 1.01-1.03, p < 0.0001) and blood transfusion (OR: 1.06; 95%CI: 1.05-1.08, p < 0.0001) at all timepoints after readmission. PD patients who experienced GI hemorrhage of any etiology, including as a side effect of anti-parkinsonism medication, were found to have significantly higher rates of blood transfusion at all timepoints (OR: 1.14; 95%CI: 1.13-1.16, p < 0.0001). Blood transfusions were found to be significantly associated with anti-parkinsonism drug side effects and GI hemorrhage of any etiology.
Sections du résumé
BACKGROUND
BACKGROUND
As evidence continues to accumulate regarding the multi-organ dysfunction associated with Parkinson's disease (PD), it is still unclear as to whether PD increases the risk of hematological pathology. In this study, the authors investigate the association between PD and hematological pathology risk factors.
METHODS
METHODS
This retrospective cohort analysis was conducted using 8 years of the National Readmission Database. All individuals diagnosed with PD were queried at the time of primary admission. Readmissions, complications, and risk factors were analyzed at 30-, 90-, 180-, and 300-day intervals. Statistical analysis included multivariate Gaussian-fitted modeling using age, sex, comorbidities, and discharge weights as covariates. Coefficients of model variables were exponentiated and interpreted as odds ratios.
RESULTS
RESULTS
The database query yielded 1,765,800 PD patients (mean age: 76.3 ± 10.4; 44.1% female). Rates of percutaneous blood transfusion in readmitted patients at 30, 90, 180, and 300 days were found to be 8.7%, 8.6%, 8.3%, and 8.3% respectively. Those with anti-parkinsonism medication side effects at the primary admission had increased rates of gastrointestinal (GI) hemorrhage (OR: 1.02; 95%CI: 1.01-1.03, p < 0.0001) and blood transfusion (OR: 1.06; 95%CI: 1.05-1.08, p < 0.0001) at all timepoints after readmission. PD patients who experienced GI hemorrhage of any etiology, including as a side effect of anti-parkinsonism medication, were found to have significantly higher rates of blood transfusion at all timepoints (OR: 1.14; 95%CI: 1.13-1.16, p < 0.0001).
CONCLUSIONS
CONCLUSIONS
Blood transfusions were found to be significantly associated with anti-parkinsonism drug side effects and GI hemorrhage of any etiology.
Identifiants
pubmed: 35499631
doi: 10.1007/s10072-022-06097-6
pii: 10.1007/s10072-022-06097-6
pmc: PMC9349070
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4761-4768Informations de copyright
© 2022. The Author(s).
Références
Elbaz A, Carcaillon L, Kab S, Moisan F (2016) Epidemiology of Parkinson’s disease. Rev Neurol 172(1):14–26
pubmed: 26718594
doi: 10.1016/j.neurol.2015.09.012
Pringsheim T, Jette N, Frolkis A, Steeves TDL (2014) The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29(13):1583–1590
pubmed: 24976103
doi: 10.1002/mds.25945
Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72(21 Suppl 4):S1–S136
pubmed: 19470958
doi: 10.1212/WNL.0b013e3181a1d44c
Marras C, Beck JC, Bower JH et al (2018) Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis 4:21
pubmed: 30003140
pmcid: 6039505
doi: 10.1038/s41531-018-0058-0
Bloem BR et al (2021) Parkinson’s disease. Lancet 397(10291):2284–2303
pubmed: 33848468
doi: 10.1016/S0140-6736(21)00218-X
Moustafa AA et al (2016) Motor symptoms in Parkinson’s disease: a unified framework. ____Neurosci Biobehav Rev 68:727–740
pubmed: 27422450
doi: 10.1016/j.neubiorev.2016.07.010
Belvisi D et al (2020) Risk factors of Parkinson disease: simultaneous assessment, interactions, ____and etiologic subtypes. Neurology 95(18):e2500–e2508
pubmed: 32943485
pmcid: 7682833
doi: 10.1212/WNL.0000000000010813
Schapira AHV et al (2017) Non-motor features of Parkinson disease. Nat Rev Neurosci 18(7):435–450
pubmed: 28592904
doi: 10.1038/nrn.2017.62
Solla P et al (2021) Frequency and determinants of olfactory hallucinations in Parkinson’s ____disease patients. Brain Sci 11(7):841. https://doi.org/10.3390/brainsci11070841
pubmed: 34202903
pmcid: 8301996
doi: 10.3390/brainsci11070841
Titova N, Chaudhuri KR (2018) Non-motor Parkinson disease: new concepts and personalised management. Med J Aust 208(9):404–409
pubmed: 29764353
doi: 10.5694/mja17.00993
Yang Y-W, Hsieh T-F, Li C-I et al (2017) Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine 96(3):e5921
pubmed: 28099356
pmcid: 5279101
doi: 10.1097/MD.0000000000005921
Santiago JA, Bottero V, Potashkin JA (2017) Biological and clinical implications of comorbidities in Parkinson’s disease. Front Aging Neurosci 9:394
pubmed: 29255414
pmcid: 5722846
doi: 10.3389/fnagi.2017.00394
Visser M, Marinus J, van Hilten JJ, Schipper RGB, Stiggelbout AM (2004) Assessing comorbidity in patients with Parkinson’s disease. Mov Disord 19(7):824–828
pubmed: 15254943
doi: 10.1002/mds.20060
Guneysel O, Onultan O, Onur O (2008) Parkinson’s disease and the frequent reasons for emergency admission. Neuropsychiatr Dis Treat. https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2536537/ .
Woodford H, Walker R (2005) Emergency hospital admissions in idiopathic Parkinson’s disease. Mov Disord 20(9):1104–1108
pubmed: 15884038
doi: 10.1002/mds.20485
Sato Y, Kaji M, Metoki N, Yoshida H, Satoh K (2003) Coagulation-fibrinolysis abnormalities in patients receiving antiparkinsonian agents. J Neurol Sci 212(1–2):55–58
pubmed: 12809999
doi: 10.1016/S0022-510X(03)00101-1
Lee K-E, Kang HS, Yu H-J, Roh SY (2013) Thrombocytopenia associated with levodopa treatment. J Mov Disord 6(1):21–22
pubmed: 24868421
pmcid: 4027649
doi: 10.14802/jmd.13005
Giner V, Rueda D, Salvador A, Hernández JC, Esteban MJ, Redón J (2003) Thrombocytopenia associated with levodopa treatment. Arch Intern Med 163(6):735–736
pubmed: 12639208
doi: 10.1001/archinte.163.6.735
Chaudhuri KR, Healy DG, Schapira AHV (2006) National Institute for Clinical Excellence Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5(3):235–245
pubmed: 16488379
doi: 10.1016/S1474-4422(06)70373-8
Mukherjee A, Biswas A, Das SK (2016) Gut dysfunction in Parkinson’s disease. World J Gastroenterol 22(25):5742–5752
pubmed: 27433087
pmcid: 4932209
doi: 10.3748/wjg.v22.i25.5742
Jain S (2011) Multi-organ autonomic dysfunction in Parkinson disease. Parkinsonism Relat Disord 17(2):77–83
pubmed: 20851033
doi: 10.1016/j.parkreldis.2010.08.022
Chandra R, Hiniker A, Kuo Y-M, Nussbaum RL, Liddle RA 2017 α-Synuclein in gut endocrine cells and its implications for Parkinson’s disease. JCI Insight. 2(12). https://doi.org/10.1172/jci.insight.92295
Liddle RA (2018) Parkinson’s disease from the gut. Brain Res 1693(Pt B):201–206
pubmed: 29360467
pmcid: 6003841
doi: 10.1016/j.brainres.2018.01.010
Sampson TR, Challis C, Jain N, et al 2020 A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice. Elife. 9. https://doi.org/10.7554/eLife.53111
Kim S, Kwon S-H, Kam T-I et al (2019) Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease. Neuron 103(4):627-641.e7
pubmed: 31255487
pmcid: 6706297
doi: 10.1016/j.neuron.2019.05.035
Kishimoto Y, Zhu W, Hosoda W, Sen JM, Mattson MP (2019) Chronic mild gut inflammation accelerates brain neuropathology and motor dysfunction in α-synuclein mutant mice. Neuromolecular Med 21(3):239–249
pubmed: 31079293
pmcid: 6701950
doi: 10.1007/s12017-019-08539-5
Quigley EMM (2017) Microbiota-brain-gut axis and neurodegenerative diseases. Curr Neurol Neurosci Rep 17(12):94
pubmed: 29039142
doi: 10.1007/s11910-017-0802-6
Westfall S, Lomis N, Kahouli I, Dia SY, Singh SP, Prakash S (2017) Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis. Cell Mol Life Sci 74(20):3769–3787
pubmed: 28643167
doi: 10.1007/s00018-017-2550-9
Ciorniciuc V. Charlson Comorbidity Index (CCI) Calculator 2020. https://www.thecalculator.co . https://www.thecalculator.co/health/Charlson-Comorbidity-Index-(CCI)-Calculator-765.html . Accessed April 17, 2020.
Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251
pubmed: 7722560
doi: 10.1016/0895-4356(94)90129-5
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383
pubmed: 3558716
doi: 10.1016/0021-9681(87)90171-8
Quan H, Li B, Couris CM et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676–682
pubmed: 21330339
doi: 10.1093/aje/kwq433
Radovanovic D, Seifert B, Urban P et al (2014) Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002–2012. Heart 100(4):288–294
pubmed: 24186563
doi: 10.1136/heartjnl-2013-304588
Pardi DS, Loftus EV Jr, Tremaine WJ et al (1999) Acute major gastrointestinal hemorrhage in inflammatory bowel disease. Gastrointest Endosc 49(2):153–157
pubmed: 9925691
doi: 10.1016/S0016-5107(99)70479-7
Struck LK, Rodnitzky RL, Dobson JK (1990) Stroke and its modification in Parkinson’s disease. Stroke 21(10):1395–1399
pubmed: 2219202
doi: 10.1161/01.STR.21.10.1395
Lim K-M, Kim H-H, Bae O-N et al (2009) Inhibition of platelet aggregation by 1-methyl-4-phenyl pyridinium ion (MPP+) through ATP depletion: evidence for the reduced platelet activities in Parkinson’s disease. Platelets 20(3):163–170
pubmed: 19437333
doi: 10.1080/09537100902721746
Sharma P, Nag D, Atam V, Seth PK, Khanna VK (1991) Platelet aggregation in patients with Parkinson’s disease. Stroke 22(12):1607–1608
pubmed: 1962340
doi: 10.1161/01.STR.22.12.1607
Shen X, Yang H, Zhang D, Jiang H (2019) Iron concentration does not differ in blood but tends to decrease in cerebrospinal fluid in Parkinson’s disease. Front Neurosci 13:939
pubmed: 31616238
pmcid: 6775209
doi: 10.3389/fnins.2019.00939
Baker JF, McClelland S 3rd, Line BG et al (2017) In-hospital complications and resource utilization following lumbar spine surgery in patients with parkinson disease: evaluation of the National Inpatient Sample database. World Neurosurg 106:470–476
pubmed: 28711540
doi: 10.1016/j.wneu.2017.07.006
Oichi T, Chikuda H, Ohya J et al (2017) Mortality and morbidity after spinal surgery in patients with Parkinson’s disease: a retrospective matched-pair cohort study. Spine J 17(4):531–537
pubmed: 27884743
doi: 10.1016/j.spinee.2016.10.024
Tana C, Lauretani F, Ticinesi A et al (2018) Molecular and clinical issues about the risk of venous thromboembolism in older patients: a focus on Parkinson’s disease and parkinsonism. Int J Mol Sci 19(5):1299
pmcid: 5983741
doi: 10.3390/ijms19051299
Adams B, Nunes JM, Page MJ et al (2019) Parkinson’s disease: a systemic inflammatory disease accompanied by bacterial inflammagens. Front Aging Neurosci 11:210
pubmed: 31507404
pmcid: 6718721
doi: 10.3389/fnagi.2019.00210
Rosenbaum H, Aharon-Peretz J, Brenner B (2013) Hypercoagulability, parkinsonism, and Gaucher disease. Semin Thromb Hemost 39(8):928–934
pubmed: 24129683
doi: 10.1055/s-0033-1357485